Simvastatin

Simvastatin is a statin, a medicine taken by mouth to lower LDL cholesterol. The FDA label says it is indicated to lower LDL cholesterol, as an adjunct to diet, in adults with primary hyperlipidemia. Zocor is the brand name on the label read.

Also called Zocor

  • Drug
  • In this atlas

Overview

Technical summary

RxNorm ingredient 36567; UNII AGG2FN16EV. MeSH descriptor D019821 is Simvastatin. Class: HMG-CoA Reductase Inhibitor (FDA established pharmacologic class, RxClass). The label read is the Organon LLC label for ZOCOR (simvastatin), application NDA019766, effective 2025-03-28 in openFDA. This page records the label indication and the class only: no trial result and no dose is given.

Trials at a glance

The figures count the 11 registry trials in this atlas that name this drug or a product that contains it. Trials that use another name for it are not counted.

Trials
11
Phase 3 or 4
8
Recruiting
0
Regulatory decisions
0
Trials by phase (rows) and registry status (columns)
PhaseCompletedTerminatedUnknown statusAll statuses
Phase 21001
Phase 2/31001
Phase 34206
Phase 41012
No phase1001
All phases82111

Conditions these trials study

Sponsors with the most trials

The lead sponsor of each trial, as the registry names it.

And 3 more.

About this drug

Level
Substance
Mechanism
Not reported

Claims and evidence

Context People for whom the US label of simvastatin lists an indication: adults with primary hyperlipidemia

Recipient
Adult
Population
Patients described in the indications section of the label, the passage read here being the adult LDL-cholesterol (LDL cholesterol) indication.
Care setting
Prescription medicine, as described in the US label
Geography
United States (label of the US Food and Drug Administration)
Life stage
Adults, as the passage read states
Follow-up
Not applicable (label statement)
Eligibility: 1 inclusion criterion; exclusion criteria not stated
Included
  • Adults with primary hyperlipidemia
Excluded
None stated
  • Description Evidence stage not applicable Certainty not assessed

    The US label of ZOCOR (simvastatin), in the Organon LLC version dated 2025-03-28 in openFDA, lists the medicine to lower LDL cholesterol, as an adjunct to diet, in adults with primary hyperlipidemia.

    Applies to Adult People for whom the US label of simvastatin lists an indication: adults with primary hyperlipidemia

    Certainty method
    Not assessed
    Limitations
    This claim records one thing the label says the medicine is indicated for. It is not a finding about how well the medicine works, and no trial result is recorded for it in this atlas. The label lists other indications that were not recorded; contraindications, doses, interactions and warnings were not read. Labels change, and openFDA also lists other versions with different dates. openFDA's own disclaimer says not to rely on it for decisions about medical care.
    Last checked
    2026-11-07
    Next evidence check due
    Not scheduled
    Sources and citations (2)
    1. Supports openFDA drug label record for ZOCOR (simvastatin), Organon LLC label: indications and substance identifiers

      Regulator · U.S. Food and Drug Administration (openFDA) · Edition The openFDA drug label record for set id 8f55d5de-5a4f-4a39-8c84-c53976dd6af9 (manufacturer Organon LLC, application NDA019766), returned on 2026-11-07. The label text is dated 2025-03-28 (effective_time). Other openFDA records of simvastatin labels from other sponsors and repackagers exist and were not used.

      Locator
      results[0].indications_and_usage[0], 1 INDICATIONS AND USAGE
      How it applies
      The label sentence that gives the LDL-cholesterol indication.
      Retrieved
      Source effective date
      2025-03-28
      Source state
      Current
      Version fingerprint
      e61cb84d9362069369e2e6ca98bae80f77907ec3102d10a9c5fc1fd15918f843
      Reuse basis
      openFDA data is public domain under a Creative Commons CC0 1.0 Universal dedication, as the openFDA licence page states (fetched 2026-11-07, sha256 7fda0041a24f8d7139a1781d4462ae39643a2ee6f3b0f079946c989a8e1982d2, hash only). Only short passages are quoted. The raw record is committed in the atlas repository.
    2. Background openFDA drug label record for ZOCOR (simvastatin), Organon LLC label: indications and substance identifiers

      Regulator · U.S. Food and Drug Administration (openFDA) · Edition The openFDA drug label record for set id 8f55d5de-5a4f-4a39-8c84-c53976dd6af9 (manufacturer Organon LLC, application NDA019766), returned on 2026-11-07. The label text is dated 2025-03-28 (effective_time). Other openFDA records of simvastatin labels from other sponsors and repackagers exist and were not used.

      Locator
      results[0].effective_time
      How it applies
      Effective date of the label text read, 20250328.
      Retrieved
      Source effective date
      2025-03-28
      Source state
      Current
      Version fingerprint
      e61cb84d9362069369e2e6ca98bae80f77907ec3102d10a9c5fc1fd15918f843
      Reuse basis
      openFDA data is public domain under a Creative Commons CC0 1.0 Universal dedication, as the openFDA licence page states (fetched 2026-11-07, sha256 7fda0041a24f8d7139a1781d4462ae39643a2ee6f3b0f079946c989a8e1982d2, hash only). Only short passages are quoted. The raw record is committed in the atlas repository.

FDA label

Assembled by a program from the openFDA drug label dataset, retrieved 8 November 2026, for the products that contain this drug: the label of the application holder or its company group, never a repackager's. Data provided by the U.S. Food and Drug Administration (open.fda.gov). The label is a manufacturer's submission that FDA has not verified, and the label on the product may differ. 1 label below.

FLOLIPID

No label from the application holder was found in the openFDA label dataset for application NDA206679. This page does not show another labeler's label in its place.

JUVISYNC

No label from the application holder was found in the openFDA label dataset for application NDA202343. This page does not show another labeler's label in its place.

SIMVASTATIN

No label from the application holder was found in the openFDA label dataset for application NDA021961. This page does not show another labeler's label in its place.

VYTORIN

Application
NDA021687
Labeler
Organon LLC
Label version
Version 9, effective
Label set id
89b860d2-de83-468e-b7e8-76aeec2edca2
Boxed warning
No boxed warning
Sections the label has
Indications and usage Contraindications Warnings and cautions Adverse reactions Drug interactions Use in specific populations Pregnancy Pediatric use Geriatric use Clinical pharmacology Clinical studies

ZOCOR

No label from the application holder was found in the openFDA label dataset for application NDA019766. This page does not show another labeler's label in its place.

FDA decisions timeline

The regulatory decisions of the FDA that this atlas holds for this drug and the products that contain it, oldest first. Each links to its full record.

  1. Approval NDA019766 ZOCOR
  2. Supplemental approval NDA019766 ZOCOR
  3. Supplemental approval NDA019766 ZOCOR
  4. Supplemental approval NDA019766 ZOCOR
  5. Supplemental approval NDA019766 ZOCOR
  6. Supplemental approval NDA019766 ZOCOR
  7. Supplemental approval NDA019766 ZOCOR
  8. Supplemental approval NDA019766 ZOCOR
  9. Supplemental approval NDA019766 ZOCOR
  10. Supplemental approval NDA019766 ZOCOR
  11. Supplemental approval NDA019766 ZOCOR
  12. Supplemental approval NDA019766 ZOCOR
  13. Supplemental approval NDA019766 ZOCOR
  14. Supplemental approval NDA019766 ZOCOR
  15. Approval NDA021687 VYTORIN
  16. Supplemental approval NDA021687 VYTORIN
  17. Supplemental approval NDA021687 VYTORIN
  18. Approval NDA021961 SIMVASTATIN
  19. Supplemental approval NDA021687 VYTORIN
  20. Approval NDA202343 JUVISYNC
  21. Supplemental approval NDA021687 VYTORIN
  22. Supplemental approval NDA202343 JUVISYNC
  23. Approval NDA206679 FLOLIPID

Clinical links

Each link reports what one cited claim says about one population. "Evaluated for" means studied, not shown to work. These links do not show that anything is effective or right for you.

Registry records

Assembled by a program from ClinicalTrials.gov and openFDA. No person wrote or checked these pages, and they are counted apart from the pages that people wrote. Lists of trials come from the registry's own coding and may miss trials.

Registry products 5

  • A new drug application (NDA) that FDA lists in Drugs@FDA, with an original approval and 13 efficacy supplement approvals on record.

    ProductNDA019766

  • A new drug application (NDA) that FDA lists in Drugs@FDA, with an original approval and 4 efficacy supplement approvals on record.

    ProductNDA021687

  • A new drug application (NDA) that FDA lists in Drugs@FDA, with an original approval and no efficacy supplement approvals on record.

    ProductNDA021961

  • A new drug application (NDA) that FDA lists in Drugs@FDA, with an original approval and 1 efficacy supplement approval on record.

    ProductNDA202343

  • A new drug application (NDA) that FDA lists in Drugs@FDA, with an original approval and no efficacy supplement approvals on record.

    ProductNDA206679

Registry trials 11

Record details

Record id
cardio:simvastatin
Content hash
d9ed39968fca3c0577509e7c0b5da8df36337c6694f25d6b9ff8c87bbdb82110